Kura Oncology (KURA) Operating Income (2010 - 2026)

Kura Oncology (KURA) reported Operating Income of -$78.8 million for Q1 2026, down 21.82% year-over-year from -$100.8 million in Q1 2025, and down 21.82% on a QoQ basis from -$64.7 million in Q1 2025.

Kura Oncology (KURA) has 7 years of Operating Income data on file, last reported at -$78.8 million in Q1 2026.

  • Quarterly Operating Income fell 21.82% year-over-year to -$78.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$143.5 million (down 121.77% YoY) and the FY2025 annual result came in at -$303.6 million, down 57.16% from the prior year.
  • Operating Income eased to -$78.8 million in Q1 2026 per KURA's latest filing, from -$64.7 million in the prior quarter.
  • Across five years, Operating Income topped out at -$64.7 million in Q1 2025 and bottomed at -$78.8 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.97 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -19.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -15.76 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.14 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.82 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 642.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 268.64 Mn
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn -78.82 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -78.82 Mn
Mar 31, 2025 -64.70 Mn
Dec 31, 2014 -9,762.00
Sep 30, 2014 -4,764.00
Jun 30, 2014 -5,242.00
Mar 31, 2014 -4,138.00
Dec 31, 2013 -8,087.00
Sep 30, 2013 -4,475.00
Jun 30, 2013 -5,456.00
Mar 31, 2013 -4,716.00
Dec 31, 2012 -8,376.00
Sep 30, 2012 -4,728.00
Jun 30, 2012 -4,996.00
Mar 31, 2012 -4,241.00
Dec 31, 2011 -7,976.00
Sep 30, 2011 -5,360.00
Jun 30, 2011 -5,837.00
Mar 31, 2011 -4,266.00
Dec 31, 2010 -7,214.00
Sep 30, 2010 -4,238.00